Roche’s personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents

Ads

You May Also Like

MorphoSys AG Reports Results for the First Six Months of 2016

Financial Guidance for 2016 Confirmed Conference call and webcast (in English) today at 2:00pm ...

TESARO Secures $500 Million Non-Dilutive Term Loan Financing

WALTHAM, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology focused ...

RedHill Biopharma Announces Withdrawal of Public Offering of its American Depositary Shares

TEL-AVIV, Israel, Nov. 02, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” ...